Medine.co.uk

Adios Max

Informations for option: Adios Max, show other option

SUMMARY OF PRODUCT CHARACTERISTICS

1 NAME OF THE MEDICINAL PRODUCT

Adios Max

2    QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains:

120 mg of extract (as dry extract) from Bladderwrack thallus (Fucus vesiculosus L.) (5:1).

Extraction solvent: Methanol 30% v/v For full list of excipients, see section 6.1.

Each tablet contains 70 mg lactose monohydrate and 130 mg sucrose and 144 micrograms of iodine (See section 4.4. ‘Special warnings and precautions for use.’)

3    PHARMACEUTICAL FORM

Coated Tablet

White, circular, biconvex sugar-coated tablets.

4    CLINICAL PARTICULARS

4.1    Therapeutic indications

A traditional herbal medicinal product used as an aid to slimming as part of a calorie controlled diet, based on traditional use only.

4.2 Posology and method of administration

For oral use only.

Adults (18 years and above): One tablet three times a day.

This product should be taken as part of a calorie-controlled diet and extra exercise.

If symptoms do not improve or worsen during the use of this medicinal product, a doctor or a qualified healthcare practitioner should be consulted. The use in children and adolescents under 18 years and the elderly is not recommended (see Section 4.4. Special warnings and precautions for use).

4.3 Contraindications

Hypersensitivity to the active substances or to iodine or to any of the excipients. Patients with a thyroid disorder.

4.4 Special warnings and precautions for use

Do not exceed the stated dose.

The use in children and adolescents under 18 years and the elderly is not recommended because data are insufficient and medical advice should be sought. Do not take with other medicines or dietary supplements containing iodine. Contains lactose and sucrose, patients with rare hereditary problems of galactose or fructose intolerance, glucose-galactose malabsorption, the Lapp lactase deficiency or sucrase-isomaltase insufficiency should not take this medicine.

4.5 Interaction with other medicinal products and other forms of interaction

No studies have been carried out to determine if drug interactions occur with this

product.

Do not take with other medicines or dietary supplements containing iodine.

Do not take with medicines for thyroid disorders

This product can theoretically have an effect on anticoagulant treatments. Patients taking anticoagulant treatments should not use the product.

4.6 Fertility, pregnancy and lactation

Safety during pregnancy and lactation has not been established.

In the absence of sufficient data the use in pregnancy and lactation is not recommended.

Studies on the effects on fertility have not been performed.

4.7 Effects on ability to drive and use machines

No studies on the effects of this product on the ability to drive or operate machinery have been performed.

4.8    Undesirable effects

May cause diarrhoea. The frequency is unknown.

If other adverse reactions not mentioned above occur, a doctor or a qualified healthcare practitioner should be consulted.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.

4.9    Overdose

An overdose may lead to thyroid disorders such as hyperthyroidism, thyrotoxicosis, subclinical hypothyroidism, Hashimoto's thyroiditis.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

5.2 Pharmacokinetic properties

Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

5.3 Preclinical safety data

Tests on reproductive toxicity, genotoxicity and carcinogenicity have not been performed.

6    PHARMACEUTICAL PARTICULARS

6.1    List of excipients

Tablet core: -

Lactose Monohydrate

Sodium Starch Glycollate

Calcium Hydrogen Phosphate Dihydrate (E341)

Talc

Magnesium Stearate

Tablet coating: -Titanium Dioxide (E171)

Talc

Kaolin Light Sucrose Acacia Shellac

6.2 Incompatibilities

None.

6.3 Shelf life

36 months

6.4    Special precautions for storage

Store in the original package

6.5    Nature and contents of container

White polypropylene containers with tamper-evident polyethylene moulded cap or integral polypropylene cap. Containing 50 or 100 tablets.

6.6 Special precautions for disposal

No special requirements.

7    MARKETING AUTHORISATION HOLDER

Brome and Schimmer Limited

T/A Diomed Herbals

Tatmore Place

Gosmore

Hitchin

Herts SG4 7QR UK

8    MARKETING AUTHORISATION NUMBER(S)

THR17418/0028

9    DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

10/04/2013

10    DATE OF REVISION OF THE TEXT

3/11/2014